MiMedx Group, Inc. (MDXG)
NASDAQ: MDXG · Real-Time Price · USD
4.240
-0.120 (-2.75%)
At close: Mar 18, 2026, 4:00 PM EDT
4.280
+0.040 (0.94%)
After-hours: Mar 18, 2026, 7:18 PM EDT

MiMedx Group Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
48.584267.44-19.95-12.3
Depreciation & Amortization
14.886.043.434.055.18
Stock-Based Compensation
16.416.9316.9611.3314.16
Other Adjustments
17.137.59-34.474.622.44
Change in Receivables
-26.39-2.55-12.24-5.94-10.62
Changes in Inventories
-1.53-2.36-7.84-1.79-1.41
Changes in Accounts Payable
2.12-1.410.780.84-0.16
Changes in Accrued Expenses
11.362.110.120.51-15.49
Changes in Other Operating Activities
-8.53-1.220.76-1.638.32
Operating Cash Flow
7466.226.78-17.89-1.98
Operating Cash Flow Growth
11.79%147.24%---
Capital Expenditures
-1.03-1.68-1.99-1.51-3.22
Purchases of Intangible Assets
-----0.25
Payments for Business Acquisitions
-3.76-7.86---
Other Investing Activities
-2.09-0.04-0.17-1.150.08
Investing Cash Flow
-6.89-9.58-2.16-2.66-3.4
Short-Term Debt Issued
-30---
Short-Term Debt Repaid
--30---
Long-Term Debt Issued
-19.78---
Long-Term Debt Repaid
-1-51---
Net Long-Term Debt Issued (Repaid)
-1-31.22---
Issuance of Common Stock
-1.410.651.44
Repurchase of Common Stock
-3.12-2.64--1.19-4.75
Net Common Stock Issued (Repurchased)
-3.12-1.241-0.54-3.31
Repurchase of Preferred Stock
---9.52--
Net Preferred Stock Issued (Repurchased)
---9.52--
Other Financing Activities
-1.29-1.74-0.05-0.04-0.04
Financing Cash Flow
-5.41-34.2-8.57-0.58-3.35
Net Cash Flow
61.7122.4216.05-21.13-8.73
Free Cash Flow
72.9764.5224.79-19.41-5.2
Free Cash Flow Growth
13.11%160.27%---
FCF Margin
17.43%18.49%7.71%-7.25%-2.15%
Free Cash Flow Per Share
0.490.430.17-0.17-0.05
Levered Free Cash Flow
64.8412.6853.49-29.74-17.05
Unlevered Free Cash Flow
98.276.06-12.22-14.12-13.67
Updated Feb 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q